IMMUNOPRECISE ANTIBODIES announces the publication for the development of a new TB diagnostic test.
IMMUNOPRECISE ANTIBODIES announces opening of its second US based office in the Boston/Cambridge area.
IMMUNOPRECISE ANTIBODIES has purchased its second state-of-the-art Intellicyt® iQue Screener PLUS for high-throughput cell-based screening, thereby increasing production volume.
IMMUNOPRECISE is excited to announce that it has appointed Lisa Helbling as CFO of the company.
IMMUNOPRECISE ANTIBODIES doubles revenues in second quarter 2019.
Meet Jennifer Bath, CEO and President, Jason Orloske, Vice President of Operations, Frederick Chabot, Contact Financial, Paul Andreola, Board Director, and Pascal Nigen, Managing Partner at Alpha Bronze, at the J.P. Morgan Healthcare Conference Week.